Key result
Beta-blocker exposure in patients with heart failure with preserved ejection fraction did not significantly alter the rates of cardiac inpatient admissions, critical care admissions, or cardiovascular death.
Why the study?
Heart failure with preserved ejection fraction lacks clear guidelines, and beta-blockade therapy has drawn attention from past meta-analyses.
Does beta-blocker therapy reduce cardiovascular death or hospital admission in adult patients with heart failure with preserved ejection fraction?
Observational (n=625)
Does beta-blocker therapy reduce cardiovascular death or hospital admission in adult patients with heart failure with preserved ejection fraction?
In a predominantly minority cohort with HFpEF, beta-blocker therapy was not associated with a reduction in cardiovascular mortality or hospital admissions.
Background: Heart failure preserved ejection fraction does not have clear guidelines. Because of past meta-analyses investigations, the Beta-blockade has sparked the most attention. Method & Results: We performed a retrospective observational where 1500 adult patients were studied from the period January 1, 2012 to December 31, 2017. After the review, 625 met the criteria to be included in the study. Cardiac reasons for inpatient admission between patients on beta-blockers vs. not on beta-blockers do not differ. The likelihood of requiring critical care admission was similar, and the likelihood of death due to cardiovascular causes between both groups did not differ. Conclusion: The use of beta-blockade therapy is still a subject of debate, especially in the minority (Hispanic and African American) population.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an observational in Heart failure with preserved ejection fraction (n=625). Beta-blockers vs. No beta-blockers was evaluated on Cardiac reasons for inpatient admission, critical care admission, and cardiovascular death. Beta-blocker exposure in patients with heart failure with preserved ejection fraction did not significantly alter the rates of cardiac inpatient admissions, critical care admissions, or cardiovascular death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: